Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis

worldpharmanewsMarch 23, 2017

Tag: Novartis , psoriasis

PharmaSources Customer Service